Vanda Pharmaceuticals (VNDA) Total Non-Current Liabilities (2011 - 2026)
Vanda Pharmaceuticals recorded quarterly Total Non-Current Liabilities of $142.6 million in Q1 2026, down 6.3% quarter-over-quarter from $152.2 million in Q4 2025, and up 28.18% year-over-year from $111.3 million in Q1 2025.
Vanda Pharmaceuticals' Total Non-Current Liabilities history runs 15 years deep, the most recent figure standing at $142.6 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 28.18% year-over-year to $142.6 million; the TTM figure through Mar 2026 stood at $142.6 million (up 28.18% YoY), while the FY2025 annual figure was $152.2 million, up 40.86% from the prior year.
- Total Non-Current Liabilities came in at $142.6 million for Q1 2026 at Vanda Pharmaceuticals, down from $152.2 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $152.2 million in Q4 2025 to a low of $92.3 million in Q3 2023.
- A 5-year average of $108.6 million and a median of $100.4 million in 2022 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities fell 9.08% in 2023 and jumped 40.86% in 2025, its largest moves.
- Vanda Pharmaceuticals' Total Non-Current Liabilities stood at $100.2 million in 2022, then dropped by 5.53% to $94.7 million in 2023, then advanced by 14.12% to $108.1 million in 2024, then jumped by 40.86% to $152.2 million in 2025, then dropped by 6.3% to $142.6 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $142.6 million, $152.2 million, and $124.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Vanda Pharmaceuticals | 379.35 Mn | 177.04 Mn | 48.56 Mn | 142.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 142.63 Mn |
| Dec 31, 2025 | 152.23 Mn |
| Sep 30, 2025 | 124.10 Mn |
| Jun 30, 2025 | 128.45 Mn |
| Mar 31, 2025 | 111.27 Mn |
| Dec 31, 2024 | 108.07 Mn |
| Sep 30, 2024 | 94.58 Mn |
| Jun 30, 2024 | 99.80 Mn |
| Mar 31, 2024 | 99.86 Mn |
| Dec 31, 2023 | 94.70 Mn |
| Sep 30, 2023 | 92.31 Mn |
| Jun 30, 2023 | 95.34 Mn |
| Mar 31, 2023 | 102.18 Mn |
| Dec 31, 2022 | 100.25 Mn |
| Sep 30, 2022 | 101.53 Mn |
| Jun 30, 2022 | 97.69 Mn |
| Mar 31, 2022 | 100.40 Mn |
| Dec 31, 2021 | 84.47 Mn |
| Sep 30, 2021 | 82.45 Mn |
| Jun 30, 2021 | 82.73 Mn |
| Mar 31, 2021 | 72.91 Mn |
| Dec 31, 2020 | 77.43 Mn |
| Sep 30, 2020 | 72.92 Mn |
| Jun 30, 2020 | 73.31 Mn |
| Mar 31, 2020 | 71.36 Mn |
| Dec 31, 2019 | 71.96 Mn |
| Sep 30, 2019 | 72.79 Mn |
| Jun 30, 2019 | 75.57 Mn |
| Mar 31, 2019 | 72.60 Mn |
| Dec 31, 2018 | 53.02 Mn |
| Sep 30, 2018 | 46.24 Mn |
| Jun 30, 2018 | 46.88 Mn |
| Mar 31, 2018 | 71.96 Mn |
| Dec 31, 2017 | 70.36 Mn |
| Sep 30, 2017 | 71.54 Mn |
| Jun 30, 2017 | 75.44 Mn |
| Mar 31, 2017 | 72.97 Mn |
| Dec 31, 2016 | 75.32 Mn |
| Sep 30, 2016 | 75.68 Mn |
| Jun 30, 2016 | 76.76 Mn |
| Mar 31, 2016 | 80.04 Mn |
| Dec 31, 2015 | 76.32 Mn |
| Sep 30, 2015 | 70.89 Mn |
| Jun 30, 2015 | 70.19 Mn |
| Mar 31, 2015 | 56.79 Mn |
| Dec 31, 2014 | 7.79 Mn |
| Sep 30, 2014 | 78.00 Mn |
| Jun 30, 2014 | 85.15 Mn |
| Mar 31, 2012 | 145.40 Mn |
| Dec 31, 2011 | 149.14 Mn |